Total trials
159
Active
15
Phase 3
51
Total enrollment
25,530
Pipeline matrix
Showing 23 of 23 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| KK8398 | — | — | — | — | — | 1 | |
| KHK4951 | — | — | — | — | 3 | ||
| Aflibercept | — | — | — | — | — | 2 | |
| ME-401 | — | — | — | — | 2 | ||
| KK8123 | — | — | — | — | — | 1 | |
| KK2430 | — | — | — | — | — | 1 | |
| ziftomenib | — | — | — | — | — | 1 | |
| KK4277 | — | — | — | — | — | 1 | |
| KK2260 | — | — | — | — | — | 1 | |
| KK2845_1 | — | — | — | — | — | 1 | |
| KK2845_2 | — | — | — | — | — | 1 | |
| KK2845_3 | — | — | — | — | — | 1 | |
| KK2845_4 | — | — | — | — | — | 1 | |
| KK2845_5 | — | — | — | — | — | 1 | |
| KK2845_6 | — | — | — | — | — | 1 | |
| KK2845_7 | — | — | — | — | — | 1 | |
| KK2845_8 | — | — | — | — | — | 1 | |
| KK2845_alternative_1 | — | — | — | — | — | 1 | |
| KK2845_alternative_2 | — | — | — | — | — | 1 | |
| KK3910 | — | — | — | — | — | 1 | |
| KK2269 | — | — | — | — | — | 1 | |
| Docetaxel | — | — | — | — | — | 1 | |
| Poteligeo 20mg | — | — | — | — | — | 1 |
Next readouts
- 2024-12-10
- 2026-08-31
- 2026-08-31
- 2027-03
- 2027-04
- 2027-12
- 2028-02-11
- 2028-05-31
- 2028-09
- 2029-03
Top conditions
- Parkinson's Disease17
- Hyperphosphatemia7
- Secondary Hyperparathyroidism6
- X-linked Hypophosphatemia5
- Aplastic Anemia4
- Type 2 Diabetes4
- Cancer4
- Chronic Kidney Disease3
Frequently asked questions about Kyowa Kirin Co., Ltd.
- How many clinical trials does Kyowa Kirin Co., Ltd. have on ClinicalTrials.gov?
- Kyowa Kirin Co., Ltd. is listed as the lead sponsor on 159 clinical trials in ClinicalTrials.gov, 15 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Kyowa Kirin Co., Ltd.'s trials are in Phase 3?
- 51 of Kyowa Kirin Co., Ltd.'s trials are in Phase 3, spread across 23 active drug programs.
- What therapeutic areas does Kyowa Kirin Co., Ltd. focus on?
- Kyowa Kirin Co., Ltd.'s most-studied conditions on ClinicalTrials.gov are Parkinson's Disease, Hyperphosphatemia, Secondary Hyperparathyroidism, X-linked Hypophosphatemia, Aplastic Anemia.
- When are Kyowa Kirin Co., Ltd.'s next clinical trial readouts?
- Kyowa Kirin Co., Ltd. has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus”, expected around 2024-12-10.